Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
Ema Ozaki,1 Matthew Campbell,1 Sarah L Doyle2,3 1Department of Genetics, 2Department of Clinical Medicine, School of Medicine, Trinity College Dublin, 3National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland Abstract: The inflammasome is a...
Saved in:
Main Authors: | Ozaki E (Author), Campbell M (Author), Doyle SL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapy targeted to the NLRP3 inflammasome in chronic kidney disease
by: Yong Ji, et al.
Published: (2024) -
Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
by: Haowen Xu, et al.
Published: (2023) -
Neurodegenerative Disease and the NLRP3 Inflammasome
by: Jonathan A. Holbrook, et al.
Published: (2021) -
The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets
by: Tao Liang, et al.
Published: (2022) -
NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies
by: Pengfei Chen, et al.
Published: (2024)